Production of a protein A - lymphotoxin hybrid protein for cancer-targeted therapy

2Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A hybrid protein between staphylococcal protein A and human lymphotoxin, ALT, was produced in Escherichia coli by expression of a recombinant plasmid containing the respective genes. IgG-binding activity of ALT was confirmed by Western blotting analysis and by affinity purification with IgG-Sepharose column chromatography. The purified ALT had cytotoxicity on mouse L-929 cells and its specific activity was approximately 3.5-5.0 × 106 U mg-1. ALT was partially degraded by a protease including in the E. coli lysate or trypsin and was converted to lymphotoxin which lacks the NH2-terminal 19 residues but possesses higher cytotoxic activity than ALT. © 1993.

Cite

CITATION STYLE

APA

Wada, M., Kasumimoto, T., Miki, T., Osada, H., & Kato, S. (1990). Production of a protein A - lymphotoxin hybrid protein for cancer-targeted therapy. Journal of Biotechnology, 13(4), 325–334. https://doi.org/10.1016/0168-1656(90)90080-U

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free